Life Sciences Tools & Services
Price
$613.78
-0.75%Market Cap
$226.9B
Day High
$615.74
Day Low
$605.52
Thermo Fisher Scientific reported strong Q2 FY2026 financial results, with revenue increasing 10.5% YoY to $11.99B and diluted EPS rising 9.3% YoY to $4.68, driven by robust pharma and biotech market demand and strategic M&A integration.
Key risk: Elevated Debt Obligations and Increased Interest Expense
Total long-term debt increased 20.7% YoY to $42.28B to fund capital deployment and acquisitions. Consequently, net interest expense increased significantly to $194M in Q2 FY2026 compared to $107M in Q2 FY2025.
Other Life Sciences Tools & Services companies